An Overview of Regorafenib in Gastrointestinal Cancers: A Lunch Clinical Research Update

Session Chair(s)

• 

  Tanios Bekaii-Saab, MD

  Mayo Clinic
  Mayo Clinic
  Scottsdale, United States

Educational activity provided by ESMO WCGIC and supported by Bayer.

Presentations:

• 13:30 – 13:35

  Welcome
  

  Session Chair: Tanios Bekaii-Saab, MD – Mayo Clinic
• 13:35 – 13:45

  Flexible Dosing and Sequencing Strategies with Regorafenib
  

  Session Speaker: Tanios Bekaii-Saab, MD – Mayo Clinic
• 13:45 – 14:00

  Regorafenib + IO agents: Why does site matter?
  

  Session Speaker: Christophe Borg
• 14:00 – 14:15

  Integrating ctDNA in Immune Response Assessment
  

  Session Speaker: Michel P. Ducreux, MD, PhD – Gustave Roussy
• 14:15 – 14:30

  Bringing Regorafenib into Earlier Lines and Stages of Therapy: Where Do We Stand
  

  Session Speaker: Paul Ross, PhD FRCP – Guy's & St Thomas' NHS Foundation Trust
• 14:30 – 14:45

  The Complicated Landscape of 2L HCC: Where Does Regorafenib Fit?
  

  Session Speaker: Richard Finn, MD – Geffen School of Medicine at UCLA
• 14:45 – 15:00

  The Current and Future Role of Regorafenib in Gastric Cancer: Focus on the INTEGRATE Study
  

  Session Speaker: Tanios Bekaii-Saab, MD – Mayo Clinic